Ivix (Russia) Overview

  • Founded
  • 2012
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $4.2M
Latest Deal Amount

Ivix (Russia) General Information


Developer of drugs designed to treat female sexual and reproductive dysfunctions. The company's drugs are produced using innovations in molecular biology and physiology which changes the activity of genes involved in the metabolism of certain neurotransmitters in the brain, enabling women to treat sexual disorders.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • Table Lane 6
  • Moscow
  • Russia
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ivix (Russia) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 25-Sep-2018 $4.2M 00.000 Completed Generating Revenue
1. Early Stage VC 01-Jan-2013 Completed Startup
To view Ivix (Russia)’s complete valuation and funding history, request access »

Ivix (Russia) Executive Team (3)

Name Title Board Seat Contact Info
Dmitry Golikov MD Chief Executive Officer & General Manager
Mikhail Lomonosov Ph.D Director for Science and Production
Elena Kasimova Director, Business Development & Board Member
To view Ivix (Russia)’s complete executive team members history, request access »

Ivix (Russia) Board Members (1)

Name Representing Role Since
Elena Kasimova Self Director, Business Development & Board Member 000 0000
To view Ivix (Russia)’s complete board members history, request access »

Ivix (Russia) Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Russian Venture Company Venture Capital Minority 000 0000 000000 0
To view Ivix (Russia)’s complete investors history, request access »